Broncus Holding Corporation (2216.HK)

0.550 -0.010 (-1.79%) As of 10:41AM HKT. Market open.

Broncus Holding Corporation

Building 8
Room 801, 8/F No. 88 Jiangling Road, Xixing Street Binjiang District
Hangzhou
China
86 571 8659 5016
https://www.broncus.com

Sector(s): Healthcare
Industry: Medical Devices
Full-time employees: 308

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Hong Xu	Chairman of the Board & CEO	1.32M	N/A	1987
Thomas M. Keast	VP, Operation Director & Scientist in resident	N/A	N/A	N/A
Feng Yao	Sr. Accountant	N/A	N/A	N/A
Ms. Elaine Lu	Director of Finance & Administration	N/A	N/A	N/A
Ms. Yin Kwan Ho	Company Secretary	N/A	N/A	1978

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in HKD.

Description

Broncus Holding Corporation, a medical device company, focuses on the development of interventional pulmonology products in Mainland China, the European Union, the United States, and internationally. The company offers InterVapor, a thermal vapor treatment system to treat chronic obstructive pulmonary disease (COPD); RF-II, transbronchial interventional treatment product for lung cancer; Targeted Lung Denervation (TLD) Ablation System for the treatment of COPD; H-Marker, treatment for lung cancer/lung nodules; disposable nebulizing micro-catheter for endoscope used for accurate anti-inflammation, local hemostasis, phlegm reduction and elimination, staining location, and local anesthesia; and BroncTru, a disposable transbronchoscopic puncture dilatation catheter. It also provides navigation products, such as LungPoint Virtual Bronchoscopic Navigation, a computer-assisted image-based navigation software system; LungPoint Plus/Archimedes Lite, a system that provides real-time navigation within the airways for lung biopsy and other procedures; and LungPoint ATV System, an archimedes system. In addition, the company offers diagnosis products, such as FleXNeedle, a multipurpose biopsy needle; Archimedes Sheath, a sterile single-use flexible tube that provides a working channel during a bronchoscopic procedure; Archimedes Dilation Balloon, a sterile single-use flexible tube with a balloon at or near the distal tip that is inserted through the bronchoscope or sheath and used to dilate the target lung tissue of the bronchial tree; and BioStarNeedle, ATV FleXNeedle CN, ATV Sheath, ATV Balloon, and Steerable Sheath. The company was incorporated in 2012 and is headquartered in Hangzhou, China.

Corporate governance

Broncus Holding Corporation’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.